GlassScriptPhysician profile
Charles D Godwin
NPI 1164496592
$1,660.74
in general payments reported to CMS, 2019-2025
20 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $29.44 · 2022: $31.27 · 2023: $567 · 2024: $466 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.85 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $332.97 | 2023-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $213.97 | 2019-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $194.91 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $144.95 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $132.16 | 2019-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $124.22 | 2023 | Quviviq |
| Abbvie INC. | $113.98 | 2024-2025 | |
| Lundbeck LLC | $90.36 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $79.39 | 2022-2023 | Qelbree |
| Bausch Health US, LLC | $32.49 | 2019-2020 | |
| Tris Pharma INC | $30.75 | 2019 | |
| Brainsway USA INC | $30.01 | 2025 | Deep Tms System |
| Sunovion Pharmaceuticals INC. | $25.28 | 2019 | |
| Alkermes, INC. | $22.60 | 2025 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $20.12 | 2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.56 | 2019 | |
| Allergan, INC. | $16.23 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.30 | 2019 | |
| Indivior INC. | $12.15 | 2019 | |
| Corium, LLC | $9.34 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Godwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.